Learn about Rx XALKORI® (crizotinib) for treatment of ALK+ or ROS1+ non-small cell lung cancer that has spread to other parts of the body. See risks & benefits.

XALKORI is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an …

XALKORI was the first ALK inhibitor and first and only ROS1 inhibitor approved in the U.S. and is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose …

Drug Indication Xalkori is a kinase inhibitor approved for the treatment of ALK- or ROS1-positive metastatic non-small-cell lung cancer (NSCLC) and for children and young adults with relapsed or …

XALKORI® (crizotinib) Clinical Studies 14 CLINICAL STUDIES 14.1 ALK- or ROS1-Positive Metastatic Non-Small Cell Lung Cancer Previously Untreated ALK-Positive Metastatic NSCLC - Study 1 …

Aug 20, 2025 · Xalkori (crizotinib) is used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) due to a genetic defect. Metastatic means the cancer has spread to other parts of …

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Treatment combined with supportive care have improved the lives of people with NSCLC.

6 days ago · Lung cancer affects more than 200,000 people in the United States annually; non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. 1-3 Lung cancer …

Jul 7, 2022 · Xalkori (crizotinib) is a targeted therapy medication. It is a treatment option for people with advanced, non-small cell lung cancer.